AtaiBeckley Inc.

Healthcare · Biotechnology · United States

Last price 7.35 USD (At close: Sep 10, 2026) · Market cap 2.73B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuro...